NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: LAURUSLABS · data 2026-11-01
Laurus Labs Ltd.
In plain words
Price: at or near its 52-week high.
Delivery: 42.6% of traded shares were kept for delivery over the last 10 sessions, against 52.3% over the last 60.
Latest results: a net profit of ₹441 cr for the quarter ended Sept 2026 (+126.4% on the same quarter a year earlier).
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹7,823 cr |
| Net profit (last 12 months) | ₹1,340 cr |
| Sales growth, 3 years (yearly) | 4.1% |
| Profit growth, 3 years (yearly) | 4.0% |
At a glance
Promoters 27.5% (-0.1 pts in a year), pledged 2.2%, institutions 42.7%.
P/E 97.1, P/B 21.4, dividend yield 0.1%. Price relative to earnings and book value (low is cheaper, not better).
ROE 18.2%, ROCE 20.5%, operating margin 24.1%: how much profit it earns on the money it uses.
Debt/equity 0.48, Profit growth 4.0% and sales growth 4.1% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- High return on equity (18.2%).
- Healthy operating margin (24.1%).
- Slow sales growth (4.1% a year over 3 years).
- Promoters have pledged 2.2% of their shares.
- Expensive on earnings (P/E 97.1).
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Latest results in brief (Q2 FY27)
LAURUSLABS Q2 FY27 results (consolidated figures, as filed on NSE).
Revenue was ₹2,206.37 crore, up 33.4% YoY and up 8.9% QoQ.
Net profit was ₹441.48 crore, up 126.4% YoY and up 20.1% QoQ.
Operating margin was 34% (24.4% a year ago).
EPS was ₹8.17, up 126.3% YoY and up 20% QoQ.
LAURUSLABS के Q2 FY27 नतीजे (कंसोलिडेटेड आंकड़े, NSE पर दाखिल)।
राजस्व: ₹2,206.37 करोड़; पिछले साल की तुलना में 33.4% की बढ़त, पिछली तिमाही की तुलना में 8.9% की बढ़त।
शुद्ध मुनाफ़ा: ₹441.48 करोड़; पिछले साल की तुलना में 126.4% की बढ़त, पिछली तिमाही की तुलना में 20.1% की बढ़त।
ऑपरेटिंग मार्जिन: 34% (एक साल पहले 24.4%)।
EPS: ₹8.17; पिछले साल की तुलना में 126.3% की बढ़त, पिछली तिमाही की तुलना में 20% की बढ़त।
LAURUSLABSના Q2 FY27 પરિણામો (કન્સોલિડેટેડ આંકડા, NSE પર ફાઇલ કરેલા).
આવક (રેવન્યુ): ₹2,206.37 કરોડ; ગયા વર્ષની સરખામણીએ 33.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 8.9% વધારો.
ચોખ્ખો નફો: ₹441.48 કરોડ; ગયા વર્ષની સરખામણીએ 126.4% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 20.1% વધારો.
ઓપરેટિંગ માર્જિન: 34% (એક વર્ષ પહેલાં 24.4%).
EPS: ₹8.17; ગયા વર્ષની સરખામણીએ 126.3% વધારો, ગયા ક્વાર્ટરની સરખામણીએ 20% વધારો.
Written from the filed numbers. Not a recommendation.
Smart-money activity
31/100 · Neutral over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 43.0% over the last 20 sessions vs 62.5% in the 40 before (0.69x); shares delivered per day 0.52x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 13/15: 38 schemes hold it, about ₹4,998 cr in all (as of 2026-09-30). Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 13/15: Verdict "Sustained", sustained score 75/100.
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Results ● Dividend
- 29 Oct 26Results Q2 FY27 results: profit +126.4% YoY +10.2% next session
- 24 Jul 26Results Q1 FY27 results: profit +125.5% YoY +9.3% next session
- 8 May 26Dividend Dividend ₹1.2 (ex-date) +5.0% next session
- 30 Apr 26Results Q4 FY26 results: profit +19.5% YoY +5.5% next session
- 23 Jan 26Results Q3 FY26 results: profit +172.7% YoY -0.6% next session
- 23 Jan 26Results Q2 FY26 results: profit +882.7% YoY -0.6% next session
- 31 Oct 25Dividend Dividend ₹0.8 (ex-date) +0.5% next session
- 23 Oct 25Results Results board meeting +0.3% next session
- 25 Jul 25Results Q1 FY26 results: profit +1203.1% YoY +6.3% next session
- 9 May 25Dividend Dividend ₹0.8 (ex-date) +1.1% next session
- 25 Apr 25Results Q4 FY25 results: profit +209.0% YoY -2.9% next session
- 24 Jan 25Results Q3 FY25 results: profit +298.9% YoY -8.6% next session
- 6 Nov 24Dividend Dividend ₹0.4 (ex-date) +1.2% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Quarterly results (consolidated)
| Quarter | Revenue | Net profit | Profit YoY | Op. margin | EPS ₹ |
|---|---|---|---|---|---|
| Sept 2026 | ₹2,206 cr | ₹441 cr | +126.4% | 34.0% | 8.17 |
| Jun 2026 | ₹2,026 cr | ₹368 cr | +125.5% | 31.5% | 6.81 |
| Mar 2026 | ₹1,812 cr | ₹279 cr | +19.5% | 28.3% | 5.17 |
| Dec 2025 | ₹1,778 cr | ₹252 cr | +172.7% | 27.0% | 4.67 |
Shareholding trend
| Holder | Sept 2026 | Jun 2026 | Mar 2026 | Dec 2025 |
|---|---|---|---|---|
| Promoters | 27.47% | 27.47% | 27.49% | 27.49% |
| Foreign institutions (FII) | 30.84% | 28.00% | 25.82% | 26.52% |
| Domestic institutions (DII) | 11.86% | 13.74% | 13.97% | 12.43% |
| Mutual funds | 8.26% | 10.15% | 11.22% | 9.49% |
| Retail investors | 12.15% | 12.64% | 13.26% | 13.65% |
| Number of shareholders | 3,11,892 | 2,91,653 | 2,92,281 | 2,80,756 |
Common questions
What was Laurus Labs Ltd.'s latest quarterly profit?
Laurus Labs Ltd. reported a net profit of ₹441 cr for the quarter ended Sept 2026 (+126.4% on the same quarter a year earlier), on revenue of ₹2,206 cr.
How much do promoters hold in Laurus Labs Ltd.?
Promoters held 27.47% of Laurus Labs Ltd. at the end of Sept 2026, with 2.19% of promoter shares pledged.
Is Laurus Labs Ltd. debt-free?
Its latest reported debt-to-equity ratio is 0.48.
What is Laurus Labs Ltd.'s P/E ratio?
About 97.1, based on the last 12 months' earnings and a price of ₹2,405.5 (data 2026-11-01).
What is the 52-week high and low of Laurus Labs Ltd.?
The 52-week high is ₹2,405.5 and the 52-week low is ₹917.95.
Mutual funds holding Laurus Labs Ltd.
From the monthly portfolios of the fund houses the site reads, as of 2026-09-30. 38 schemes holding about ₹4,998 cr; funds that hold it outside their top holdings may not be listed.
| Scheme | Fund house | % of fund | Value |
|---|---|---|---|
| Mirae Asset Large & Midcap Fund | Mirae Asset Mutual Fund | 4.10% | ₹1,756 cr |
| Mirae Asset ELSS Tax Saver Fund | Mirae Asset Mutual Fund | 4.55% | ₹1,120 cr |
| Mirae Asset Midcap Fund | Mirae Asset Mutual Fund | 4.31% | ₹842 cr |
| SBI Healthcare Opportunities Fund | SBI Mutual Fund | 4.05% | ₹238 cr |
| Mirae Asset Aggressive Hybrid Fund | Mirae Asset Mutual Fund | 2.12% | ₹196 cr |
| Mirae Asset Healthcare Fund | Mirae Asset Mutual Fund | 5.51% | ₹193 cr |
| Nippon India Nifty Pharma ETF | Nippon India Mutual Fund | 7.82% | ₹136 cr |
| Nippon India Nifty 500 Momentum 50 Index Fund | Nippon India Mutual Fund | 6.16% | ₹79 cr |
| ADITYA BIRLA SUN LIFE QUANT FUND | Aditya Birla Sun Life Mutual Fund | 4.03% | ₹75 cr |
| Nippon India ETF Nifty Midcap 150 | Nippon India Mutual Fund | 1.91% | ₹73 cr |
| Nippon India Nifty Midcap 150 Index Fund | Nippon India Mutual Fund | 1.91% | ₹51 cr |
| Mirae Asset Multi Asset Allocation Fund | Mirae Asset Mutual Fund | 1.13% | ₹41 cr |
| Mirae Asset Nifty Midcap 150 ETF | Mirae Asset Mutual Fund | 1.90% | ₹35 cr |
| Mirae Asset Balanced Advantage Fund | Mirae Asset Mutual Fund | 1.24% | ₹26 cr |
| SBI Nifty Midcap 150 Index Fund | SBI Mutual Fund | 1.90% | ₹24 cr |
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Laurus Labs Ltd. | ₹2,405.5 | ₹1,29,243 cr | 97.1 | 21.5 | 18.2% | 20.5% | 0.48 | +149.8% |
| Torrent Pharmaceuticals Ltd | ₹4,613.4 | ₹1,76,300 cr | 75.6 | 9.6 | 27.1% | 13.5% | 1.79 | +28.0% |
| Zydus Lifesciences Limited | ₹1,245.5 | ₹1,24,089 cr | 27.8 | — | 19.7% | 17.8% | 0.46 | +24.1% |
| Dr. Reddy's Laboratories Ltd. | ₹1,352 | ₹1,12,643 cr | 40.3 | 2.9 | 12.1% | 12.1% | 0.21 | +13.0% |
| Mankind Pharma Ltd. | ₹2,492.8 | ₹1,02,797 cr | 46 | 5.9 | 12.5% | 12.7% | 0.39 | +1.4% |
| Glenmark Pharmaceuticals Limited | ₹2,298.7 | ₹65,137 cr | 36.1 | — | 14.1% | 29.2% | 0.06 | +24.1% |
Compare LAURUSLABS with TORNTPHARM in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open LAURUSLABS in NSE Scanner →